A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Tracon Pharmaceuticals Inc.
Sponsor:
Information provided by (Responsible Party):
Tracon Pharmaceuticals Inc.
ClinicalTrials.gov Identifier:
NCT01806064
First received: February 26, 2013
Last updated: May 5, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2014
  Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)